# Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

> **NCT01525407** · PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 83 (actual)

## Conditions studied

- Malignant Neoplasm

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Atorvastatin Calcium
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT01525407
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2015-09
- **Final completion:** 2016-02
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2017-08-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01525407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01525407, "Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01525407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*